Journal article · 2022 · Open access

74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective

Christian Jackisch, Malgorzata Joanna Banys-Paluchowski, Agnieszka Korfel, C. Stoffregen, T. Otto, Jaqueline Brown, Isaac Sanderson, Alex Rider, Diana Lüftner

Annals of Oncology, 33, S156–S157 · Published 1 May 2022 · DOI 10.1016/j.annonc.2022.03.090

Open full textCite this paper

In brief

“74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective” is a 2022 journal article by Christian Jackisch and 8 co-authors, published in Annals of Oncology. OpenAlex counts 0 citations as of 22 November 2026. It is open access: the full text is free to read at Annals of Oncology.

Citations
0
Authors
9

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Jackisch, C., Banys-Paluchowski, M. J., Korfel, A., Stoffregen, C., Otto, T., Brown, J., Sanderson, I., Rider, A., & Lüftner, D. (2022). 74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective. Annals of Oncology, 33, S156–S157. https://doi.org/10.1016/j.annonc.2022.03.090

MLA 9

Jackisch, Christian, et al. “74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective.” Annals of Oncology, vol. 33, 2022, pp. S156–S157. https://doi.org/10.1016/j.annonc.2022.03.090.

Chicago

Jackisch, Christian, Malgorzata Joanna Banys-Paluchowski, Agnieszka Korfel, C. Stoffregen, T. Otto, Jaqueline Brown, Isaac Sanderson, Alex Rider, and Diana Lüftner. 2022. “74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective.” Annals of Oncology 33: S156–S157. https://doi.org/10.1016/j.annonc.2022.03.090.

Harvard

Jackisch, C. et al. (2022) ‘74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective’, Annals of Oncology, 33, pp. S156–S157. doi:10.1016/j.annonc.2022.03.090.

IEEE

C. Jackisch et al., “74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective,” Annals of Oncology, vol. 33, pp. S156–S157, 2022, doi: 10.1016/j.annonc.2022.03.090.

BibTeX

@article{jackisch2022management,
  title     = {{74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective}},
  author    = {Jackisch, Christian and Banys-Paluchowski, Malgorzata Joanna and Korfel, Agnieszka and Stoffregen, C. and Otto, T. and Brown, Jaqueline and Sanderson, Isaac and Rider, Alex and Lüftner, Diana},
  journal   = {Annals of Oncology},
  year      = {2022},
  volume    = {33},
  pages     = {S156--S157},
  doi       = {10.1016/j.annonc.2022.03.090},
  url       = {https://doi.org/10.1016/j.annonc.2022.03.090}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies

  • early breast cancer
  • hormone receptor-positive breast cancer
  • HER2-negative breast cancer
  • patient perspectives
  • patient satisfaction
  • coping with illness
  • patient involvement in treatment decisions
  • adjuvant therapy

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Jackisch, C., Banys-Paluchowski, M. J., Korfel, A., Stoffregen, C., Otto, T., Brown, J., Sanderson, I., Rider, A., & Lüftner, D. (2022). 74P Management of early-stage hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-word setting in Germany: A patient perspective. Annals of Oncology, 33, S156–S157. https://doi.org/10.1016/j.annonc.2022.03.090

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of Oncology: sign in and open the full text from this page.

Who wrote this paper?

Christian Jackisch, Malgorzata Joanna Banys-Paluchowski, Agnieszka Korfel, C. Stoffregen, T. Otto, Jaqueline Brown, Isaac Sanderson, Alex Rider, Diana Lüftner.

What is the DOI of this paper?

10.1016/j.annonc.2022.03.090, permanently at https://doi.org/10.1016/j.annonc.2022.03.090. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.